A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

Original reporting
Published Nov 3, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$AQST
Bullish
high confidence
Mentioned
$AQST
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$AQSTBullishHigh
01

Why it matters

The NDA resubmission is a fresh regulatory milestone that could materially affect AQST's valuation ahead of the March 2027 PDUFA deadline.

02

Market read

Regulatory progress for a novel allergy treatment creates a near‑term trading catalyst for AQST and may set a precedent for oral epinephrine products.

03

What to watch

The commercial launch timeline and reimbursement landscape remain uncertain, which could limit upside

Relevance 7/10Novelty 8/10Timing: ahead of investor call on Nov 4, 2026

Background

Aquestive Therapeutics provided a Q3 2026 financial update and detailed its pipeline, highlighting the Anaphylm oral rescue medication as a key upcoming product.

Company-level read

Ticker impact

$AQSTBullishHigh confidence
Context

AQST announced resubmission of its Anaphylm NDA to the FDA with a PDUFA goal date of March 16, 2027, marking the first public disclosure of this regulatory step.

Expected impact

likely upside as investors price in potential approval and market entry

Evidence & confidence

Regulatory progress for a first‑in‑class oral epinephrine product is material for a biotech; the market typically reacts positively to forward‑looking FDA milestones.

Market effects

strengthens the allergy‑treatment sub‑sector and may boost peer biotech valuations

U.S. biotech market sees added upside; Canadian and EU markets watch for parallel filings

potentially influences global allergy‑medication pipelines and related specialty pharma stocks

Counterpoint

If the FDA raises additional concerns, the stock could face a sharp decline despite the resubmission

Key entities

  • Aquestive Therapeutics, Inc.

    Biopharmaceutical company developing oral epinephrine products

  • Daniel Barber

    President and CEO of Aquestive, quoted on the FDA resubmission

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.

$AQSTMed

Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA Resubmission

Aquestive Therapeutics (AQST) announced the FDA accepted its resubmission for Anaphylm, a sublingual epinephrine film for severe allergic reactions. The FDA set a PDUFA goal date of March 16, 2027. The company addressed prior FDA concerns in the resubmission. If approved, Anaphylm could offer a needle-free treatment option. AQST stock closed at $4.61, up 1.30% in pre-market trading.